Abstract: A consensus conference including thirty experts was held in April, 2007, to discuss risk factors for breast cancer and their management. Four categories of risk were outlined, from breast cancer ‘‘average’’ through ‘‘very high’’ risk, the latter including individuals with high penetrance BRCA1⁄ 2 gene mutations. Guidelines for management of patients in each of these categories were discussed, with the major portion of the conference being devoted to individuals with BRCA1⁄ 2 mutations. Prevalence of these mutations in the general populations was estimated to be 1 in 250–500 individuals, with an increased prevalence in Ashkenazic Jews and other founder groups. Risk reduction strategies for these individuals include surveillan...
A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutatio...
IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospecti...
Cancer survivors harboring inherited pathogenic variants in the breast cancer (BC) susceptibility ge...
Abstract: A consensus conference including thirty experts was held in April, 2007, to discuss risk f...
Germline mutations in BRCA1/BRCA2 significantly increase the risk of breast and ovarian cancer in wo...
BRCA1/2-related breast cancers (BC) can be considered a separate entity compared to sporadic ones. C...
© 2019 American Medical Association. All rights reserved. Importance: Potentially harmful mutations ...
ImportancePotentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) ...
The identification of women at higher risk for breast cancer is a matter of public health and anyone...
Importance: Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2...
Introduction.Breast cancer gene 1 and 2 (BRCA1/2) mutation carriers are at a higher risk of developi...
Pathogenic mutations in two autosomal dominant genes, BRCA1 and BRCA2 , with high penetrance are ...
Background Reliable estimates of cancer risk are critical for guiding management of BRCA1 and BRC...
Women who harbor mutations in breast cancer susceptibility genes are at an increased lifetime risk o...
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospect...
A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutatio...
IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospecti...
Cancer survivors harboring inherited pathogenic variants in the breast cancer (BC) susceptibility ge...
Abstract: A consensus conference including thirty experts was held in April, 2007, to discuss risk f...
Germline mutations in BRCA1/BRCA2 significantly increase the risk of breast and ovarian cancer in wo...
BRCA1/2-related breast cancers (BC) can be considered a separate entity compared to sporadic ones. C...
© 2019 American Medical Association. All rights reserved. Importance: Potentially harmful mutations ...
ImportancePotentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) ...
The identification of women at higher risk for breast cancer is a matter of public health and anyone...
Importance: Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2...
Introduction.Breast cancer gene 1 and 2 (BRCA1/2) mutation carriers are at a higher risk of developi...
Pathogenic mutations in two autosomal dominant genes, BRCA1 and BRCA2 , with high penetrance are ...
Background Reliable estimates of cancer risk are critical for guiding management of BRCA1 and BRC...
Women who harbor mutations in breast cancer susceptibility genes are at an increased lifetime risk o...
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospect...
A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutatio...
IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospecti...
Cancer survivors harboring inherited pathogenic variants in the breast cancer (BC) susceptibility ge...